New Clinical Trials Open for Sarcomas and Solid Tumors
Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and solid tumors. For BRAF B600 […]
Washington University School of Medicine in St. Louis Awarded $10.9 Million SPORE Grant for Pancreas Cancer
New Clinical Trials Set for Pancreatic Ductal Adenocarcinoma Clinical researchers at Washington University School of Medicine in St. Louis have been awarded a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Awarded in July 2023, it marks the […]
New Clinical Trials for Prostate, Kidney Cancers
Siteman Cancer Center has three new clinical trials open focused on prostate and kidney cancers. The first, a Phase II clinical trial testing a neoadjuvant immunotherapy treatment for prostate cancer, is available for men who have been diagnosed with localized prostate cancer. The study will evaluate the use of atezolizumab alone and in combination with […]
Early Phase Clinical Trial Focuses on Reducing Tumor Growth and Bone Loss in Patients with Breast Cancer and Bone Metastasis
Beginning next year, Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital will initiate a new early phase clinical trial aimed at stopping bone loss and cancer progression in patients with metastatic breast cancer (MBC). The trial is based on promising laboratory research conducted at the School of Medicine that showed a […]
Think Clinical Trials after First Diagnosis
Advances in cancer care are happening every day. What’s the best way to find the latest treatment options available for your patients? Check for clinical trials. While many patients think clinical trials are for those who have exhausted all current standard-of-care (SoC) treatments for their type of cancer, the best time to consider participation in […]